RU2003135201A - Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами - Google Patents

Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами Download PDF

Info

Publication number
RU2003135201A
RU2003135201A RU2003135201/15A RU2003135201A RU2003135201A RU 2003135201 A RU2003135201 A RU 2003135201A RU 2003135201/15 A RU2003135201/15 A RU 2003135201/15A RU 2003135201 A RU2003135201 A RU 2003135201A RU 2003135201 A RU2003135201 A RU 2003135201A
Authority
RU
Russia
Prior art keywords
naltrexone
morphine
prevention
control
per
Prior art date
Application number
RU2003135201/15A
Other languages
English (en)
Inventor
ВАЛЬДУЧЧИ Роберто (IT)
Вальдуччи Роберто
АЛИГЬЕРИ Тициано (IT)
АЛИГЬЕРИ Тициано
АВАНЕССЯН Серож (IT)
АВАНЕССЯН Серож
м РАФФАЕЛИ Виль (IT)
РАФФАЕЛИ Вильям
Original Assignee
Вальфарма С.А. (Sm)
Вальфарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вальфарма С.А. (Sm), Вальфарма С.А. filed Critical Вальфарма С.А. (Sm)
Publication of RU2003135201A publication Critical patent/RU2003135201A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Medicinal Preparation (AREA)

Claims (6)

1. Применение налтрексона для приготовления фармацевтических композиций, пригодных для предупреждения и контроля побочных воздействий, которые связаны с лечением морфином, предназначенных для перорального введения в дозе от 0,01 до 0,9 мг на мг вводимого морфина.
2. Фармацевтические композиции в состоящей из нескольких ингредиентов форме, пригодные для контроля побочных воздействий, которые связаны с лечением морфином, отличающиеся тем, что они представляют собой сахарозные и крахмальные гранулы, на которые нанесено покрытие из поливинилпирролидона и слой налтрексона.
3. Композиция по п.2, в которой содержание налтрексона составляет 0,005-0,1 мг на 1 мг композиции.
4. Композиция по п.2, приготовленная в виде твердых желатиновых капсул, в которых содержание налтрексона составляет 0,25-0,9 мг на стандартную дозу композиции.
5. Терапевтический способ для контроля побочных воздействий, которые связаны с лечением морфином, предусматривающий пероральное введение композиции по п.2, из расчета от 0,01 до 0,9 мг налтрексона на 1 мг морфина.
6. Способ по п.5, где введение налтрексона осуществляют за 0,5 ч до введения морфина.
RU2003135201/15A 2001-05-02 2002-05-02 Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами RU2003135201A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2001A000907 2001-05-02
IT2001MI000907A ITMI20010907A1 (it) 2001-05-02 2001-05-02 Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi

Publications (1)

Publication Number Publication Date
RU2003135201A true RU2003135201A (ru) 2005-03-27

Family

ID=11447580

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003135201/15A RU2003135201A (ru) 2001-05-02 2002-05-02 Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами

Country Status (5)

Country Link
EP (1) EP1395260A1 (ru)
IT (1) ITMI20010907A1 (ru)
RU (1) RU2003135201A (ru)
WO (1) WO2002087582A1 (ru)
ZA (1) ZA200309333B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US9056054B2 (en) 2009-06-25 2015-06-16 Elite Laboratories, Inc. Abuse resistant oral dosage forms
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20200022974A1 (en) 2018-07-23 2020-01-23 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
ATE323491T1 (de) * 1997-12-22 2006-05-15 Euro Celtique Sa Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
US6525062B2 (en) * 2000-06-09 2003-02-25 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists

Also Published As

Publication number Publication date
ITMI20010907A0 (it) 2001-05-02
ZA200309333B (en) 2004-02-17
WO2002087582A1 (en) 2002-11-07
ITMI20010907A1 (it) 2002-11-02
EP1395260A1 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
KR100417490B1 (ko) 오피오이드 제형의 남용을 방지하는 방법
RU2004106619A (ru) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
JP2004515455A (ja) オピオイドアンタゴニスト組成物および投薬形態
US20170333422A1 (en) Morphinan Derivatives for the Treatment of Drug Overdose
US20030191147A1 (en) Opioid antagonist compositions and dosage forms
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
US20100093712A1 (en) Two-component pharmaceutical composition for the treatment of pain
JP2005515966A5 (ru)
JP2003534378A (ja) フェンタニル型構造のオピオイドおよびケタミンを含有する有効成分の組合せ
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
WO2011008298A2 (en) Novel axomadol dosage forms
RU2003116058A (ru) Композиции гидрокодона с контролируемым высвобождением
JP2005512995A5 (ru)
JP2005511647A (ja) 経口用および口内用の成型粉薬錠剤を伴う圧縮環状錠剤
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
CA2709905A1 (en) Abuse-resistant oxycodone composition
TW200836738A (en) Improvements in or relating to medicinal compositions
CN1747725A (zh) 用于治疗上呼吸道阻塞的组合物及方法
JPH08512322A (ja) Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
AU2001259458A1 (en) Opioid antagonist compositions and dosage forms
RU2004107501A (ru) Способ лечения алкоголизма или злоупотребления алкоголем
MXPA02003670A (es) Sales y bases de 17-(ciclopropilmetil)-4,5 alfa-epoxi-6-metilenomorfinan-3,14 diol para optimizar la homeostasis de dopamina durante la administracion de analgesicos.
RU2003135201A (ru) Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами
JP2575569B2 (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
WO2004006929A1 (ja) 経鼻吸収用組成物

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20020502